3 results
Objective: To demonstrate the non-inferiority of ertugliflozin compared with anon-ertugliflozin comparator group on the time to first occurrence of any of thecomponents of the composite endpoint of cardiovascular death, non-fatal…
Primary: To compare the pharmacokinetics (PK) of the once daily (QD) and once weekly (QW) formulations of setmelanotideSecondary Objectives:To assess the safety of the QW formulation of setmelanotide with up to 6 months (26 weeks) of drug…
The primary objective of this study is to evaluate efficacy of erdafitinib versus chemotherapy orpembrolizumab in subjects with advanced urothelial cancer harboring selected FGFR aberrations whohave progressed after 1 or 2 prior treatments, at least…